Drug Profile

Somatropin biosimilar - AryaTinaGene

Latest Information Update: 26 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AryaTinaGene Biopharmaceuticals
Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
Mechanism of Action Human growth hormone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Somatotropin deficiency

Most Recent Events

26 Jul 2022 Somatropin biosimilar is still in phase III trials for Somatotropin deficiency (In children) in Iran (SC) (IRCT20171122037571N1)
11 Nov 2021 AryaTinaGene Biopharmaceuticals completes enrolment in its phase III trial for Somatotropin deficiency (In children) in Iran (SC) (IRCT20171122037571N1)
05 May 2019 Phase-III clinical trials in Somatotropin deficiency (In children) in Iran (SC)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com